EUVIMEDEUVIMED entdecken
Crossref

Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity

Wenxi Huang iD, Pareeta Kotecha iD, Stephen E Kimmel, Richard Segal, Jasmine D Gonzalvo, Angela Marija Pecoski, Davene Wright, Jiang Bian, Steven M Smith, Jingchuan Guo iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11475-11484

DOI: 10.1111/dom.71299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.09.2026. Verfasst von Wenxi Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Drug Monitoring, Pediatric Obesity. Die Arbeit nennt 39 Literaturangaben. Gefördert von: NIDDK NIH HHS, NIH/NIDDK, American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in Health Outcomes Disparities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for obesity treatment, but real‐world adherence patterns, particularly among individuals without diabetes and paediatric patients, remain poorly characterised. We aimed to identify 12‐month GLP‐1 RA adherence trajectories among adults and paediatric patients with obesity without diabetes and to evaluate factors associated with adherence. Materials and Methods We conducted a retrospective cohort study using 2021–2023 MarketScan commercial claims data. Individuals aged ≥ 10 years with obesity without diabetes who initiated GLP‐1 RAs were included. Adherence was measured as monthly proportion of days covered (PDC) over 12 months. Group‐based trajectory modelling was conducted separately in adult and paediatric cohorts. Multivariable logistic regression was used to identify factors associated with membership in the persistent‐user trajectory.

Results

The study included 201 229 adults and 1139 paediatric patients. Five adherence trajectories were identified in each cohort. Among adults, trajectories included immediate discontinuers (19.6%), early discontinuers (23.5%), late discontinuers (20.7%), intermittent adherents (5.5%) and persistent users (30.7%), with mean annual PDC ranging from 0.10 to 0.87. Paediatric trajectory groups were more evenly distributed, with each group representing approximately 18%–22% of the cohort and persistent users comprising 20.3%. Geographic region was consistently associated with adherence, with higher odds of persistent use in the Northeast versus the South among adults (odds ratio [OR], 1.32) and paediatric patients (OR, 1.65).

Conclusions

Most adults and paediatric patients with obesity had suboptimal adherence to GLP‐1 RA use over 12 months. Distinct adherence trajectories and consistent regional differences highlight opportunities to better understand and address barriers to long‐term obesity pharmacotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityDrug MonitoringPediatric ObesityHumansRetrospective StudiesMaleFemaleChildAdultAdolescentMiddle AgedYoung Adult

Stichwörter der Autor:innen

GLP‐1 receptor agonistsgroup‐based trajectory modelingmedication adherenceobesityreal‐world evidence

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Pharmacy Practice, College of Pharmacy, Purdue University, Indianapolis, Indiana, USA.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute LLC, East Boston, Massachusetts, USA.
  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Bloomington, Indiana, USA.

ORCID-Profile: Wenxi Huang, Pareeta Kotecha, Jingchuan Guo

Förderung

  • NIDDK NIH HHS
  • NIH/NIDDK
  • American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in Health Outcomes Disparities
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Foundation for Pharmaceutical Education

Zitieren

APA

Huang, W., Kotecha, P., Kimmel, S. E., Segal, R., Gonzalvo, J. D., Pecoski, A. M., Wright, D., Bian, J., Smith, S. M., & Guo, J. (2026). Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity. Diabetes, Obesity and Metabolism, 28(12), 11475-11484. https://doi.org/10.1111/dom.71299

Vancouver

Huang W, Kotecha P, Kimmel SE, Segal R, Gonzalvo JD, Pecoski AM, et al. Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity. Diabetes, Obesity and Metabolism. 2026;28(12):11475-11484. doi:10.1111/dom.71299

BibTeX
@article{Huang2026,
  author = {Huang, Wenxi and Kotecha, Pareeta and Kimmel, Stephen E and Segal, Richard and Gonzalvo, Jasmine D and Pecoski, Angela Marija and Wright, Davene and Bian, Jiang and Smith, Steven M and Guo, Jingchuan},
  title = {Real‐World Adherence Trajectories of GLP ‐1 Receptor Agonists Among Adults and Paediatric Patients With Obesity},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11475--11484},
  doi = {10.1111/dom.71299}
}
Kostenlos starten →